Haemonetics Corporation (HAE) delivered adjusted earnings per share (EPS) of $1.12 in the second quarter of fiscal 2025, up 13.1% year over year. The bottom line surpassed the Zacks Consensus Estimate by 2.8%.On a GAAP basis, the EPS was 66 cents compared with 48 cents in the prior-year quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement on Nov. 7, shares of HAE increased 1% in Friday’s session, finishing at $87.42.HAE’s Q2 Total RevenuesRevenue ...

Financial Data and Key Metrics - Q2 revenue was $346 million, a 9% reported growth and 4% organic growth, primarily driven by the hospital business [7] - Year-to-date revenue growth was 8% reported and 3% organic [7] - Q2 adjusted EPS was $1.12, a 13% increase YoY [7] - Adjusted gross margin reached 56.7%, up 270 basis points YoY, with 70% of the improvement driven by volume and mix [30] - Adjusted operating income was $83.5 million, up $15 million, reflecting a 310 basis point sequential expansion [33] - Adjusted net income was $57.3 million, up $7 million or 13% YoY [36] - Free cash flow was $20.4 million, compared to $84.8 million in fiscal 2024 [41] Business Unit Performance - Plasma revenue declined 3% in Q2 and year-to-date, primarily due to CSL's planned transition [10] - Software revenue was flat in Q2 but grew 10% year-to-date, driven by NexLynk DMS upgrades [11] - Hospital revenue grew 31% reported and 16% organic in Q2, driven by Blood Management Technologies and TEG growth [17][18] - Interventional Technologies grew 61% in Q2 and 64% year-to-date, driven by the successful launch of VASCADE MVP XL [20][21] - Newly acquired products contributed $16 million in Q2 and $34 million year-to-date [23] Market Performance - North America disposables revenue declined 3% in Q2, primarily due to CSL's transition [10] - Europe showed strong collections momentum, with recent volume pressures considered transitory [11] - China faced market challenges, particularly in TEG 5000 pricing, contributing to a 5% corporate revenue share [75] Strategic Direction and Industry Competition - The company is upgrading its NexSys platform and accelerating technology upgrades across U.S. centers, expecting completion this fiscal year [12] - The company is gaining market share in plasma collection and converting competitors' centers with its enhanced NexSys platform [13] - The company is expanding its presence in the rapidly growing pulsed field ablation market with VASCADE MVP XL [21] - The company is focusing on expanding its market share in electrophysiology and building a foundation in interventional cardiology and structural heart [25] Management Commentary on Operating Environment and Future Outlook - The company reaffirmed its total revenue growth expectation for fiscal 2025 in the range of 5% to 8% and raised organic growth guidance to 1% to 4% [9] - The company expects a return to more rapid plasma collections in the near to intermediate term, driven by strong end-market demand for Ig therapies [14] - The company raised its organic revenue growth guidance for the Hospital business to 14% to 17% [26] - The company remains confident in achieving short- and long-term goals, navigating complex market challenges, and adapting to emerging trends [28] Other Important Information - The company entered into an accelerated share repurchase agreement to buy back $75 million of common stock [39] - The company has $150 million remaining under its existing share repurchase authorization [40] - The company expects working capital to improve in the second half of the year and reaffirmed its free cash flow guidance for fiscal 2025 at $130 million to $180 million [43] Q&A Session Summary Question: Adoption and pricing dynamics of VASCADE MVP XL - VASCADE MVP XL has been introduced in nearly half of the existing accounts, with strong feedback on ease of use and functionality [53] - The company expects high 20% growth in the second half of the year, driven by continued penetration and pricing reflecting the value proposition [54][55] Question: Plasma business dynamics excluding CSL - Excluding CSL, the plasma business grew on pricing, driven by technology upgrades, despite a mild pullback in volumes [57][58] Question: Adjusted operating margin and cost-cutting - The company expects flattish operating margins in Q3, with a bump in Q4, driven by mix improvements and investments in clinical teams [64][65] Question: Acquired products in the Hospital segment - The company remains bullish on acquired products, with slower-than-expected progress due to market dynamics, particularly in PFA [67][68] Question: TEG market performance - TEG growth was strong in the U.S. and Europe, driven by the heparinase neutralization cartridge, while China faced pricing challenges [74][75] Question: VASCADE growth trajectory - The company expects continued accelerated growth for VASCADE, driven by market penetration and international expansion [87][88] Question: Blood Center margin stability - The company is focusing on margin expansion in the Blood Center business, particularly in the plasma collections segment [91][92] Question: Clinical investments and OpSens rollout - The company is making clinical investments to support growth, particularly in the OpSens and VASCADE product lines [97][98] Question: International launch of VASCADE - The company is ahead of schedule in Japan and building momentum in Europe, with international expansion being a key growth driver [102][103] Question: Plasma share gains - The company expects to gain momentum in plasma share gains moving into FY 2026, driven by technology upgrades [105][106] Question: VASCADE MVP XL labeling expansion - The company is working on expanding the label for VASCADE MVP XL, with FDA support expected [110][112] Question: Currency impact on margins - Currency is expected to remain a headwind in the second half of the year, depending on prevailing rates [113] Question: CSL contribution - CSL is expected to contribute approximately $100 million in fiscal 2025, with 70% already realized in the first half [114] Question: M&A strategy - The company's immediate priority is delivering on recent acquisitions, with a focus on tuck-in acquisitions and opportunistic share buybacks [117][118]

Haemonetics (HAE) reported $345.51 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 8.6%. EPS of $1.12 for the same period compares to $0.99 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $343.02 million, representing a surprise of +0.73%. The company delivered an EPS surprise of +2.75%, with the consensus EPS estimate being $1.09.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...

Haemonetics (HAE) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $0.99 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.75%. A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $1.03 per share when it actually produced earnings of $1.02, delive ...

Financial release accessible onlineBOSTON, Nov. 7, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024, are available on its Investor Relations website.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 7, 2024. The conference call and webcast can be accessed with the following information: Te ...

Analysts on Wall Street project that Haemonetics (HAE) will announce quarterly earnings of $1.09 per share in its forthcoming report, representing an increase of 10.1% year over year. Revenues are projected to reach $343.02 million, increasing 7.8% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a compa ...

Core Insights - Donidalorsen is an investigational RNA-targeted medicine aimed at preventing attacks of hereditary angioedema (HAE) and is set for FDA review with a PDUFA date of August 21, 2025 [1][3] - The drug has shown significant efficacy in clinical trials, with a 96% mean reduction in HAE attack rates maintained over three years in the ongoing Phase 2 open-label extension study [4] - Ionis Pharmaceuticals is preparing for its second independent commercial launch, contingent on FDA approval, and has partnered with Otsuka for commercialization in Europe and Asia Pacific [3][4] Company Overview - Ionis Pharmaceuticals has a history of developing RNA-targeted medicines and currently has five marketed products, focusing on areas of high patient need such as neurology and cardiology [8] - The company aims to deliver innovative therapies for serious diseases, leveraging its expertise in RNA technology and disease biology [8] Industry Context - HAE is a rare genetic condition affecting over 20,000 patients in the U.S. and Europe, characterized by recurrent severe swelling [6] - Current treatments for HAE are limited, and many patients still experience breakthrough attacks, highlighting the need for effective prophylactic options like donidalorsen [3][6]

Haemonetics (HAE) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on November 7, 2024, might help the stock move higher if these key numbers are better tha ...

Core Insights - Intellia Therapeutics, Inc. (NASDAQ: NTLA) experienced a significant stock decline of up to 20% following the release of data from its phase 1/2 study of the CRISPR/Cas9 gene editing drug NTLA-2002 [1] Company Overview - Intellia Therapeutics is focused on developing CRISPR/Cas9 gene editing therapies, with NTLA-2002 being a key product in its pipeline [1] Market Context - The article highlights the volatility in biotech stocks, particularly in response to clinical trial data releases, which can lead to substantial price fluctuations [1]

Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002’s potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in ...